Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders
Funds the discovery and first evaluation of biomarkers for neurological and neuromuscular disorders, ending with candidates ready for formal validation.
Neurological drug trials fail expensively because there is often no reliable way to tell whether the drug is doing anything. A usable biomarker changes that, and this notice funds getting one to the starting line.
The work is discovery and early evaluation of strong candidate biomarkers and biomarker signatures for neurological and neuromuscular disorders. Signatures matter as much as single mark…
Discovery and early biological, analytical and clinical evaluation of candidate biomarkers and biomarker signatures for neurological and neuromuscular disorders, including animal studies but requiring preliminary human evaluation with carefully standardised human samples or datasets, delivering candidates ready for definitive analytical and clinical validation. Clinical trials are optional.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up